title: (-)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice.
abstract: Risks of secondary lung cancer in patients with non-small cell lung cancer and small cell lung cancer are estimated to be 1-2% and 2-10% per patient per year, respectively. Cisplatin is widely used in the treatment of lung cancer and is also known as a carcinogen in experimental animals. In this study, the effect of (-)-epigallocatechin gallate (EGCG) on cisplatin-induced lung tumors in A/J mice was investigated. Female A/J mice (4 weeks old) were divided into four groups: group 1, control without treatment; group 2, EGCG treatment (1 mg/ml in tap water); group 3, weekly cisplatin treatment (1.62 mg/kg body wt, i.p.) for 10 weeks; group 4, cisplatin plus EGCG treatment (EGCG was started 2 weeks before cisplatin treatment). Four groups of mice were killed at week 30 after treatment. Tumor incidence was 26.3% (5/19) in group 1, 30% (6/20) in group 2, 100% (19/19) in group 3 and 94.4% (17/18) in group 4. Tumor multiplicity (the number of tumors per mouse, mean +/- SD) was 0.4 +/- 0.8 in group 1, 0.4 +/- 0.8 in group 2, 5.1 +/- 2.1 in group 3 and 2.8 +/- 2.3 in group 4. Tumor multiplicity was significantly reduced by adding EGCG to cisplatin-treated mice (P < 0.01). Furthermore, EGCG significantly reduced cisplatin-induced weight loss from 24.7-26.3% (cisplatin treatment) to 10.8-11.6% (cisplatin plus EGCG treatment) (P < 0.01). These findings suggest that EGCG can inhibit cisplatin-induced weight loss and lung tumorigenesis in A/J mice.
authors.affiliation: Second Department of Medicine, Second Department of Pathology, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Mimoto
authors.forename: K
authors.initials: K
authors.lastname: Kiura
authors.forename: K
authors.initials: K
authors.lastname: Matsuo
authors.forename: T
authors.initials: T
authors.lastname: Yoshino
authors.forename: I
authors.initials: I
authors.lastname: Takata
authors.forename: H
authors.initials: H
authors.lastname: Ueoka
authors.forename: M
authors.initials: M
authors.lastname: Kataoka
authors.forename: M
authors.initials: M
authors.lastname: Harada
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D002392:Catechin / Q000031:analogs & derivatives* / Q000494:pharmacology; D002945:Cisplatin / Q000037:antagonists & inhibitors* / Q000633:toxicity; D005260:Female; D008175:Lung Neoplasms / Q000139:chemically induced* / Q000517:prevention & control*; D051379:Mice
chemical_list: D016588:Anticarcinogenic Agents; D002392:Catechin; C045651:epigallocatechin gallate; D002945:Cisplatin